FDA PDUFA Performance Hampered By Inadequate Staffing – OND’s Jenkins
Executive Summary
Staffing issues are affecting FDA performance goals as the agency enters the fourth iteration of the Prescription Drug User Fee Act
You may also be interested in...
FDA Misses User Fee Goals As Resources Tighten For Application Reviews, SPAs
With the ink of the reauthorized Prescription Drug User Fee Act still drying, FDA is signaling that it may be some time before the agency will consistently meet the performance goals of its user fee program
FDA Misses User Fee Goals As Resources Tighten For Application Reviews, SPAs
With the ink of the reauthorized Prescription Drug User Fee Act still drying, FDA is signaling that it may be some time before the agency will consistently meet the performance goals of its user fee program
PDUFA IV Is “Golden Opportunity” To Improve Drug Safety Funding And Staff
The current round of reauthorization of the Prescription Drug User Fee Act presents a "golden opportunity" to improve FDA's regulation of drug safety, according to the Institute of Medicine's Assessment of the U.S. Drug Safety System Committee